The clinical effectiveness of inhaled budesonide combined with oral montelukast versus intranasal budesonide in the treatment of mild to moderate asthma complicated with seasonal allergic rhinitis in children

Objective To observe the clinical efficacy of inhaled budesonide combined with montelukast or with intranasal budesonide in pediatric asthma subjects complicating with seasonal allergic rhinitis.Methods 78 children with mild to moderate asthma complicated with seasonal allergic rhinitis were randomly allocated into three groups:intranasal budesnide for 1 month and inhaled budesonide for 6 months;montelukast for 1 month and inhaled budesonide for 6 months;montelukast for 3 months and inhaled budesonide for 6 months.The patients were followed-up for 6 months.Symptom scores of asthma and rhinitis,need for short-acting β_2 agonist and peak expiratory flow rate were recorded.Results After 6 month treatment the daytime and night symptom scores,usage of short-acting β_2 agonist and peak flow rate were improved markedly without significant difference among the three treatment groups.Conclusion[WTBZ] Our observation suggests that addition-on of montelukast for 1 month to relative low-dose inhaled budesonide can significantly control both asthma symptoms and seasonal allergic rhinitis symptoms and improved lung function with relative lower consumption of β_2 agonist and steroids.